An additional study of the T1D Exchange data examining SGLT2 inhibitors found that these medications were not associated with improvements in A1C, similar to our findings among patients receiving SGLT2 inhibitors [14]. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.